Tiger Biotherapeutics Inc. is a regenerative medicine company that develops and provides advanced cellular, acellular, and matrix-like products (CAMPs) for wound care, aesthetics, and tissue science. The company serves healthcare providers and patients by offering solutions for tissue repair, wound closure, and reconstructive or cosmetic applications.
Subscribe to see Tiger Biotherapeutics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Tiger Biotherapeutics Inc. is a biotechnology & medical technology company headquartered in Cranbury, United States. Its most recent funding round raised $20M in March 2023. Xcout tracks 8 named people at Tiger Biotherapeutics Inc., including Caroline Van Hove (President, Tiger Aesthetics Medical).
As of 16 November 2026. Source: Xcout Intel.
2 more named people on record for Tiger Biotherapeutics Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $20M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Tiger Biotherapeutics Inc.'s closest competitors — see the full list of competitors and alternatives →
Healshape is a regenerative medicine startup headquartered in Lyon, France, founded in 2020 to develop 3D bioprinted breast implants for innovative breast reconstruction.
Truelastin Laboratories develops natural elastin biomaterials and product platforms for human health applications. The company serves the medical aesthetics and therapeutic sectors by creating tissue-engineered products and advanced drug delivery systems.
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
NeXtGen Biologics, Inc. is a medical equipment manufacturing and biotechnology company located in Alachua, Florida, specializing in advanced regenerative medicine.
Regenity Biosciences is a medical device supplier and biotechnology company headquartered in Paramus, New Jersey, specializing in regenerative medicine and collagen matrix products with nearly 30 years of history.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Tiger Biotherapeutics Inc.? Suggest a correction · Work at Tiger Biotherapeutics Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.